Skip to content


  • Poster presentation
  • Open Access

Pharmacological CCR1 blockade limits infarct size and preserves cardiac function in a chronic model of myocardial ischemia/reperfusion

  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Critical Care201115 (Suppl 1) :P4

  • Published:


  • Infarct Size
  • Diastolic Function
  • Chemokine Receptor CCR1
  • CCR1 Antagonist
  • Promising Therapeutic Approach


This study sought to determine the chronic effects of pharmacological blockade of the chemokine receptor CCR1 via application of the potent, selective antagonist BX471 in a murine model of myocardial ischemia/reperfusion (I/R). CCR1 is a prominent receptor in mediating inflammatory leukocyte recruitment. The intense inflammatory response is considered to be a key component of cardiac remodelling. Thus, limiting the post-reperfusion inflammatory pattern seems to be a promising therapeutic approach in limiting reperfusion injury. Previously, we demonstrated that CCR1-/- mice exhibit attenuated infarct expansion and preserved LV function in a chronic model of myocardial no-reflow infarction due to an abrogated inflammatory response.


C57/B6 mice underwent a 60-minute coronary occlusion in a closed-chest model of myocardial I/R. Mice were treated with the specific CCR1 antagonist, BX471 (50 mg/kg BW, s.c.), or placebo, for 96 hours at 8-hour intervals starting 15 minutes prior to reperfusion. At 21 days of reperfusion, cardiac function was assessed using a pressure- volume catheter (Millar) inserted in the left ventricle. Infarct size was analysed and cardiac content for collagen was elucidated.


Infarct size was significantly smaller in the BX471-treated group (placebo: 20.7 ± 2.8% vs. BX471: 11.6 ± 4.2%, P < 0.05; area at risk did no differ between the groups). At 21 days of reperfusion BX471-treated mice exhibited a tendency towards improved cardiac function. Significantly improved diastolic function was documented in BX471-treated mice (dP/dtmin placebo: -7,635 ± 1,090 vs. BX471: -9,845 ± 657, P < 0.01). In histochemical analysis, collagen content was elevated in the hearts of BX471-treated mice.


Pharmacological CCR1 antagonism leads to improved diastolic function and attenuated infarct size in a chronic model of ischemia/reperfusion, suggesting that CCR1 antagonism might provide a promising therapeutic approach in myocardial infarction. The increased cardiac collagen documented in the treated group of our study might point towards a beneficial effect in the restructuring of the extracellular collagen matrix. Further studies of the underlying mechanisms and a detailed analysis of structural remodelling after pharmacological CCR1 blockade are warranted.

Authors’ Affiliations

Department of Cardiology, Pulmonary Diseases and Vascular Medicine, University Hospital, Düsseldorf, Germany